NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Alzamend Neuro, Inc. (ALZN) Stock Analysis

Alzamend Neuro, Inc. (ALZN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ALZN

$1.66

−$0.04 (−2.35%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ALZN with… →

ALZN Key Statistics

As of Sep 4, 2026
Trading
Open
$1.70
Previous Close
$1.70
Day's Range
1.65–1.73
52-Week Range
0.84–2.68
Volume
63.20K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.24
Valuation
Market Cap
$8.01M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.60
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$8.77M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
4.83M
1-Year Return
−26.87%
Dividend and dates
Avg Volume
160.49K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ALZN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−8.79%
2025−82.57%
2024−86.97%
2023−89.50%
2022−70.26%
2021 (partial year)−85.93%

As of September 4, 2026.

ALZN Revenue and Earnings by Fiscal Year

FY ends April
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$8.77M—
2024$0.00−$4.51M—
2023$0.00−$9.95M—
2022$0.00−$14.88M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$8.77M−$8.77M—
2024$0.00—−$4.50M−$4.51M—
2023$0.00—−$9.94M−$9.95M—
2022$0.00—−$14.87M−$14.88M—

Annual figures as reported, in the company's reporting currency. As of April 30, 2026.

ALZN Valuation vs Biotechnology Median

Median of 656 stocks
MetricALZNBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Alzamend Neuro, Inc. (ALZN) carries a market capitalisation of $8.01M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 4.

ALZN last closed at $1.66 on September 4, 2026. That is −$0.04 (−2.35%) against the previous close. The 52-week range on file runs from $0.84 to $2.68. The latest close sits 97.62% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $8.77M. The reported profit margin is 0%. Trailing earnings per share are −2.6.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at 0.24. Daily returns over the trailing 5 years annualize to a volatility of 125.93%. The trailing one-year price return is −26.87%. Across 5 years the annualized return works out at −79.16%.

Growth & Income

The record shows no dividend for ALZN.

2026 is still running; the price is −8.79% year to date. The strongest complete calendar year on file is 2022 at −70.26%; the weakest is 2023 at −89.50%. Of the 4 complete calendar years on file, 0 finished higher.

Peer Comparison

Alzamend Neuro, Inc. (ALZN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Alzamend Neuro, Inc. ALZN $8.01M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Alzamend Neuro, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Alzamend Neuro, Inc.

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Visit website →